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ABSTRACT: The development of point-of-care detection meth-
odologies for biologically relevant analytes that can facilitate rapid
and appropriate treatment is at the forefront of current research
efforts and interests. Among the various approaches, those
exploiting host−guest chemistries where the optoelectronic signals
of the chemical sensor can be modulated upon interaction with the
target analyte are of particular interest. In aiding their rational
development, judicious selection of peripheral functional groups
anchored to core motifs with desired properties is critical. Herein,
we report an in-depth investigation of the binding of three
psychoactive substances, MDAI, mexedrone, and phenibut, to
receptors of the monoamine transporters for dopamine, norepinephrine, and serotonin, particularly focusing on the role of individual
amino acid residues. We first evaluated the conformational flexibility of the ligands by comparing their experimentally determined
crystal structure geometries to those optimized by means of quantum as well as molecular mechanics, observing significant changes
in the case of phenibut. Molecular docking studies were employed to identify preferential binding sites by means of calculated
docking scores. In all cases, irrespective of the monoamine transporter, psychoactive substances exhibited preferred interaction with
the S1 or central site of the proteins, in line with previous studies. However, we observed that experimental trends for their relative
potency on the three transporters were only reproduced in the case of mexedrone. Subsequently, to further understand these findings
and to pave the way for the rational development of superior chemical sensors for these substances, we computed the individual
contributions of each nearest neighbor amino acid residue to the binding to the target analytes. Interestingly, these results are now in
agreement with those experimental potency trends. In addition, these observations were in all cases associated with key
intermolecular interactions with neighboring residues, such as tyrosine and aspartic acid, in the binding of the ligands to the
monoamine transporter for dopamine. As a result, we believe this work will be of interest to those engaged in the rational
development of chemical sensors for small molecule analytes as well as to those interested in the use of computational approaches to
further understand protein−ligand interactions.
■ INTRODUCTION
Among the plethora of chemicals that regulate normal brain
function, monoamine transporters (MATs) are widely
considered to play a critically important role.1,2 Located in
the plasma membranes of the monoaminergic neurons, they
consist of 12 transmembrane helices and are responsible for
the release or reuptake of the monoamines dopamine,
norepinephrine, and serotonin, which have biological roles
spanning from mood stabilization and appetite to sexual
arousal and decision making.3−7
Dopamine concentrations in the brain, which are modulated
by the dopamine transporter (DAT), can be further modified
by ligands that interact with the protein by either inhibiting the
reuptake of dopamine and leading to feelings of euphoria or by
stimulating the release of synaptic dopamine (i.e., amphet-
amine), associated with increased confidence and levels of
energy.4,8,9 In turn, the serotonin monoamine transporter
(SERT) is responsible for maintaining normal concentrations
of serotonin in the brain, with unregulated concentrations
resulting in a number of disorders such as anxiety, depression,
and impaired cognitive function.10,11 In relation to the
norepinephrine transporter (NET), which recycles the three
monoamines from the synapse to the presynaptic neurons,
there exist a smaller number of selective ligands that have been
identified to date in comparison to ligands that are selective
toward the other two monoamine transporters, which can be
accounted for on the basis of the structural similarity between
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the DAT and the NET.12−15 The latter can be further ascribed
to the large structural similarities among the three mono-
amines, particularly in the cases of dopamine and norepi-
nephrine (Figure 1), leading to a degree of promiscuity
between them and their associated transporters and
furthermore to the development of drugs that exhibit affinities
to all three monoamine transporters.3,7,12,16,17 Along those
lines and associated with the extensive roles in cognitive and
emotional processes played by monoamine transporters, drug
substances such as cocaine, amphetamine, and ecstasy, which
are structurally related to the monoamines, have been
extensively utilized recreationally to alter the monoamine
transporter levels within the brain to elicit some form of
psychoactive response.18−20 More recently, the so-called novel
psychoactive substances (NPSs), which denote compounds
that intend to imitate the psychoactive effects of other
controlled ones in an attempt to bypass existing regulations,
have emerged in the illegal markets for recreational
substances.21,22 Primarily due to their associated fast rate of
appearance and their low residence time in these markets,
there is an acknowledged lack of easily accessible detection and
identification platforms for NPSs that prevent rapid and
appropriate treatment. The latter further makes them a critical
social and health problem of worldwide concern.23 Consider-
ing these characteristics of NPSs, the development of point-of-
care detection methodologies for NPSs is at the forefront of
research interests and efforts.24
Drugs, recreational or therapeutic, act on target receptors via
appropriate supramolecular interactions to either trigger or
block biological responses. That concept, widely exploited by
pharmacophore modeling approaches in ligand-based drug
development methodologies,25−27 has also been utilized in the
rational development of chemical sensors.28 These method-
ologies exploit host−guest type chemistries whereby the
interaction leads to measurable changes in the optoelectronic
properties of the host, hence facilitating the detection of the
target analyte. As a result, in-depth understanding of the
intermolecular interactions that would foster selective binding
between the chemical sensor (host) and the target analyte
(guest) is deemed critical in the development of novel sensing
platforms for biologically relevant analytes, such as psycho-
active substances. In most cases, those interactions are
noncovalent in nature, which although individually weak,
play a critical role in defining the overall binding affinities and
associate conformational changes in a plethora of key processes
that are not limited to protein-binding interactions and drug
development but that further span to other topical areas of
research such as charge-transfer mechanisms in optoelectronic
materials.29−34
Along those lines, understanding any structural causation
upon interaction between ligands and receptors would be
invaluable in aiding the development of selective chemical
sensors for their target analytes, by guiding the selection of
peripheral substitutions performed on core motifs with the
desired optoelectronic properties. To that end, computational
approaches such as those denoted by molecular docking
studies are nowadays ubiquitous in providing insightful
structural and enthalpic information regarding three-dimen-
sional “weakly” bonded host−guest complexes, such as those
formed between ligands and receptors in target pro-
teins.25,30,32,33 In molecular docking, each potential orientation
of both the ligand and the receptor in the supramolecular
complex is referred to as a pose. Poses are evaluated based on
the ligand−protein affinity utilizing so-called scoring functions,
where a “good score” is attributed to potentially successful
binding interactions. In short, scoring functions can be broadly
divided into knowledge-based scoring functions and energy
component methods. The former are derived using the
probability of known relevant intermolecular interactions
from a large database. In turn, energy component methods
denote scoring functions where the free energy (ΔG) following
a supramolecular binding interaction process can be broken
down into the sum of contributions such as the specific
ligand−protein interactions as well as conformation changes
upon binding.35 However, in the quest to rationally develop
novel sensing platforms for target analytes that exploit host−
guest chemistries, knowledge of individual enthalpic contribu-
tions from amino acid residues would pave the way for the
realization of superior technologies. Despite the large number
of amino acid residues surrounding the ligands in the binding
pocket of target proteins, the strength of the overall interaction
is often uniquely dictated by a few key residues. These key
amino acids can be called so due to exhibiting close
interatomic distances with respect to the ligand and/or
presenting appropriate relative orientations as to maximize
the strength of the interaction.35 In addition, on formation of
the host−guest complex, both the binding pocket and ligand
are likely to adopt an ad hoc conformation. The extent of those
structural changes is also evaluated by scoring functions. As a
result, an aspect of interest in molecular docking studies is the
identification of biologically relevant conformations within the
landscape of all possible three-dimensional arrangements.
While relevant protein conformations can be afforded by
means of protein X-ray crystallography, NMR studies, or more
often, by homology modeling, the biological relevance of the
yielded conformations of ligands denotes an ongoing debate
within the molecular docking community25,36 and can be
partially ascribed to the intrinsically large structural flexibility
of small molecules. In most cases and in the absence of
crystallographic data, the geometries of ligands are obtained by
following geometry optimization protocols using molecular
mechanics, which are implemented in most commercially
available molecular docking packages.25,26,37 The latter, while
denoting an appropriate approach for the rapid screening over
a large data set of potential energy minima, lacks the accuracy
of higher level quantum mechanics calculations.25 Although in
some cases, conformations of systems in the crystal structures
of protein−ligand complexes are significantly less stable than
energy minimum geometries,38−40 access to experimentally
determined crystallographic data of biologically relevant
analytes is of paramount importance. This is particularly
relevant in cases where crystallographic information is scarce,
such as in the case of psychoactive substances.
Motivated by these shortcomings, herein, we report an in-
depth in silico evaluation of the binding of psychoactive
substances to target receptors in monoamine transporters,
Figure 1. Chemical structures for dopamine, norepinephrine, and
serotonin.
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particularly focused on the contributions of individual amino
acid residues to such a binding event. Among the plethora of
psychoactive substances, we selected MDAI, mexedrone, and
phenibut in our study (Figure 2) based on their current
relevance, the available literature, and their known interaction
with the monoamine transporters.22,41−45 To the best of our
knowledge, this is the first study carrying out an in-depth
investigation of the individual amino acid contributions to the
overall binding interaction of psychoactive substances to
receptors of those target proteins. To achieve that, we first
optimized the geometries of the selected psychoactive
substances (ligands) by means of molecular as well as quantum
mechanics approaches and compared them to experimentally
solved crystal structures to further understand their structural
flexibility. Subsequently, the three optimized geometries for
each ligand were docked against the three monoamine
transporter proteins, namely, the DAT, the NET and the
SERT. Evaluation of their docking scores highlights the critical
impact of the conformation of the ligand, particularly in those
structures with greater flexibility such as phenibut. Importantly,
we observed that while the computed docking scores for the
three MATs conformed to the experimentally determined
potency trends for mexedrone, that was not the case for MDAI.
With the aim of further investigating these observations and
aiding in the rational design of superior point-of-care detection
methodologies for psychoactive substances exploiting the
modulation of the optoelectronic properties of the sensor
upon interaction with the target analyte, we went on to
quantify the individual contributions by means of quantum
mechanics calculations. To do that, the three-dimensional
coordinates of both ligands and receptors were extracted from
the highest ranked poses and the intermolecular interactions of
the psychoactive substance with each nearest neighboring
amino acid residue calculated using a dimeric model. We
observed that pharmacological trends were accounted for by
our calculations in all cases. Importantly, in-depth evaluation of
the individual amino acid contributions revealed the dominant
role played by key amino acid residues, particularly those
aromatic such as phenylalanine and tyrosine, in determining
the strength of the binding and anticipate the importance of
judiciously selecting peripheral substitutions in chemical
sensors as well as core motifs to favor selective recognition.
As a result, we believe this study to be of interest not only for
those using computational approaches to understand protein−
ligand interactions but more importantly, to the increasingly
large community devoted to the development of superior
point-of-care methodologies for biologically relevant analytes.
■ EXPERIMENTAL SECTION
Reagents and Materials. Hydrochloric acid was pur-
chased from Fisher Scientific and used as received without any
further purification. Reference standard materials (purity
≥98%) for mexedrone, MDAI, and phenibut were all
purchased from Chiron AS (Trondheim, Norway) under UK
Home Office License and used as supplied.
Preparation of Crystals for Single-Crystal X-ray
Diffraction Analysis. Single crystals for mexedrone, MDAI,
and phenibut were obtained by slow evaporation of cooled
acidified (HCl) water solutions.
Crystal Structure Determination. All crystallographic
measurements were made at 123(2) K with an Oxford
Diffraction Gemini S diffractometer and monochromated Cu
radiation (λ = 1.54184 Å). Programs from the SHELX suite
were used for structure solution and refinement.46 Refinement
was to convergence against F2 using all unique reflections.
Non-H atoms were refined anisotropically. All H atoms bound
to C were observed in difference maps but were included in the
final model as riding atoms. The H atoms bound to O or to N
were refined freely and isotropically. Selected crystallographic
and refinement parameters are given in the Supporting
Information (Table SI1.1). The crystal structure of mexe-
drone·HCl reported herein only exhibits small differences with
respect to the one previously solved.47 CCDC 1989619 to
1989621 contain the supplementary crystallographic data for
this structure. These data can be obtained free of charge from
the Cambridge Crystallographic Data Centre via www.ccdc.ac.
uk/data_request/cif.
Molecular Docking Studies. Binding sites for all three
monoamine transporters were elucidated utilizing the Molec-
ular Operating Environment (MOE)48 and then cross-
referenced with the available literature to ensure that all
residues considered to be important to binding were contained
within the putative binding sites defined.15,49 For the
dopamine and norepinephrine transporters, the crystal
structure of the Drosophila dopamine transporter in complex
with the psychostimulant D-amphetamine (accession number
4XP9)15 and cocaine (accession number 4XP4)15 were used,
respectively. The crystal structure of the ts3 human serotonin
transporter complexed with S-citalopram at the central site and
Br-citalopram at the allosteric site was used for the serotonin
transporter (accession number 5I75).49 Binding was carried
out in the central site in all cases. Cavities were defined by
probe radii 1 and 2 of 1.4 and 1.8 Å, respectively, a connection
distance of 2.5 Å, and a minimum size of 3 residues.
Geometries for protonated forms of the three ligands were
optimized by means of the MMFF9450 force field as built in
MOE’s “quick-prep” methodology as well as the M06-2X51
density functional at the 6-311G(d) level as implemented in
Spartan ‘18 (v. 1.3.0),52 without applying any constrains
(Tables S2.1−S2.7). Geometries optimized with the latter
were subjected to infrared analysis returning non-negative
frequencies in all cases, consistent with a true equilibrium
minimum.37,53,54 It is noteworthy that the crystal structure
conformation was selected as the starting point for the
optimization by quantum mechanics. In turn, molecular
mechanics optimization was carried out imputing the geo-
metries as SMILES strings. Experimentally obtained crystal
structure geometries were subjected to hydrogen atom
optimization prior to docking studies following our previously
reported method,55 employing the M06-2X51 density func-
tional at the 6-311G(d) level as implemented in Spartan ‘18 (v.
1.3.0).52 Single-point energies of the H-optimized crystal
structure geometries as well as MMFF94-optimized systems
were calculated at the M06-2X/6-311G(d) level for further
comparison.
Figure 2. Chemical structures for mexedrone, MDAI, and phenibut.
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Protein models were prepared prior to inducing fit docking
studies in MOE employing the MMFF94 force field.50
Docking was carried out within the MOE package employing
the triangle matcher placement method with a rigid receptor
refinement to allow for a better comparison of the results for
different geometries of the ligands. Poses were selected based
on London ΔG and generalized-Born volume integral/
weighted surface area (GWVI/WSA) energy component
method scoring functions, with the number of docked poses
generated set to a maximum of 30 or until the conformation of
the ligand reached a default RMSD cutoff value of 3.0 Å.
Computation of Intermolecular Interactions. MOE-
induced fit docking outputs (coordinates) were extracted for
all investigated protein−ligand complexes and nearest neighbor
amino acid residues selected using an interatomic distance
cutoff value of 4.5 Å. Binding energies between each ligand and
the nearest neighbor amino acid residues were then calculated
within the framework of a dimeric model by means of
Truhlar’s density functional M06-2X51 at the 6-311G(d) level
as implemented in Spartan ‘18 (v.1.3.0) software.52 All
computed intermolecular interactions were corrected for
basis set superposition error (BSSE) by means of the
counterpoise method of Boys and Bernardi.56
■ RESULTS AND DISCUSSION
Structural Flexibility of the Ligands. Most small
molecules are intrinsically characterized by a large structural
flexibility, which inevitably leads to concerns when trying to
obtain biologically relevant conformations for docking
studies.25,38 It is noteworthy that in some cases, experimentally
determined conformations by means of X-ray crystallography
are significantly less stable than the geometry at the global
minimum and in some cases do not even correspond to
geometries at local minima.38−40 However, these are critical in
the assessment of computationally optimized geometries. As a
result, we deemed of interest to investigate in detail the yielded
ligand conformations that the three psychoactive substances
exhibit by means of commonly used molecular mechanics
protocols implemented in commercial molecular docking
software with those obtained by means of quantum mechanics
calculations as well as X-ray crystallographic studies. For all
three protonated ligands, namely, mexedrone, MDAI, and
phenibut, we report molecular mechanics as well as
experimental crystal structure geometries, which are less stable
than their conformations yielded by quantum mechanics
calculations. In short, while the differences with the crystal
structures can be attributed to interactions with neighboring
monomers as well as solvent molecules during the crystal
growth process as opposed to quantum mechanics calculations,
the comparison with molecular mechanics-yielded geometries
could be associated with starting conformations in those
calculations.
In the case of both MDAI and mexedrone, the largest
differences were observed between quantum and molecular
mechanics optimized conformations (ΔE = 24.85 kJ mol−1)
and between optimized quantum mechanics and experimental
crystal structure geometries (ΔE = 24.53 kJ mol−1),
respectively. Interestingly, we compute a significantly less
stable molecular mechanics conformation of phenibut when
compared to its crystal structure counterpart (ΔE = 86.84 kJ
mol−1) and to a greater extent with respect to its quantum
mechanics counterpart (ΔE = 110.07 kJ mol−1). In some cases,
large conformational reorganization energies can be attributed
to variations in bond lengths between the two geometries.57
However, here, detailed analysis of the variations in bond
lengths for all investigated ligands reveals no significant
changes that could account for the observed energy differences
between conformations. Instead, we observed that unlike for
the different yielded conformations for MDAI and mexedrone,
the optimized geometry of phenibut by means of molecular
mechanics exhibits a critical structural difference with respect
to the quantum mechanics-optimized geometry as well as
experimental crystal structure geometry as illustrated in Figure
3. It should be noted that the geometry of the crystal structure
was utilized as the starting point in quantum mechanics
geometry optimization calculations, whereas molecular me-
chanics geometry optimizations were performed from SMILES
strings inputs, hence lacking three-dimensional information.
Figure 3 illustrates the conformations of phenibut yielded for
the three different approaches utilized in this work. The
conformations particularly differ on the orientation of the
protonated amine with respect to the plane of the benzene
ring, with the crystal structure and quantum mechanics
geometries exhibiting an exo-type conformation of the amine
group with measured dihedral angles of θ = 178.26 and
148.93°, respectively. In turn, the optimized geometry by
molecular mechanics from SMILES strings is characterized by
an endo-type conformation (θ = 50.72°) where the amine is
closely situated above the plane of the benzene ring, which we
anticipate could lead to a reduced number of intermolecular
interactions with neighboring amino acid residues. As a result,
we investigated this further. It could be argued that the
conformation obtained by molecular mechanics denotes local
minima situated in a different region to that of the energy
minima yielded by quantum mechanics, along the potential
energy surface. To further evaluate this observation, we went
on optimizing the molecular mechanics geometry by means of
quantum mechanics. We observed that the newly optimized
geometry (Table S2.5) exhibits no negative frequencies on the
computed infrared spectrum and hence conforms to the
geometry of energy minima. The resulting conformation,
similar to the case of its molecular mechanics counterpart, is
characterized by an endo-type arrangement of the amine with
respect to the benzene ring (θ = 51.59°). As a result, these
findings highlight the importance of evaluating the con-
formations of ligands, particularly in molecular docking studies.
In the following, we examine in detail the docking scores
obtained for the different conformations of the three
investigated psychoactive substances in their target proteins.
Molecular Docking Studies. The ability of the three
psychoactive substances to interact with plasma membrane
monoamine transporters was investigated using molecular
docking studies. In all cases, the geometries of both ligands and
proteins were kept rigid upon binding to facilitate further
Figure 3. Phenibut conformations yielded by quantum mechanics
optimization (left), docking studies using molecular mechanics
(center), and crystal structure (right).
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evaluation of any structural causation to the interaction
process. Yielded poses were rank-ordered employing their
docking scores, with the following analysis focusing on the top
ranked pose for each conformation evaluated (Tables S3.1−
S3.9).
In agreement with previous studies,15,49 we report that in all
investigated cases and irrespective of the rank order of the
pose, the preferred binding site was the so-called central or S1
site, which in the case of the serotonin transporter is located
between helices 1, 3, 6, 8, and 10.49 Table 1 summarizes the
docking scores for the highest ranked poses for the different
evaluated conformations of each psychoactive substance in all
three monoamine transporters.
Careful analysis of these results reveal that different ligand
conformations have a negligible impact on the computed
docking scores for the top poses of MDAI-containing
complexes, which can be attributed to the small flexibility of
this psychoactive substance when compared to mexedrone and
phenibut (vide supra). Our computational docking results
indicate that, in agreement with experimental studies,19,58
MDAI acts on all three monoamine transporters. However, the
often-observed higher potency of MDAI on the NET and the
SERT when compared to that on the DAT is not fully
accounted for by our docking results, hence warranting further
computational studies on the docking of this psychoactive
substance. This is particularly interesting given the large
structural similarity between the DAT and the NET.15,49 In
this regard, evaluation of the position of the ligand exhibiting
the crystal structure geometry within the cavity of the central
binding site of the three MATs is consistent with small
differences in the scoring values for docking onto the DAT and
the NET, attributed to a similar sequence of nearest
neighboring amino acids bordering the ligand. Although
scoring factors consider other aspects of the binding process
and not just the intermolecular interactions, the latter can be
associated with fewer and longer distance interactions with
amino acid residues when compared to docking on the other
transporters and will be accordingly analyzed in depth in the
following section.
The highest ranked poses for mexedrone and phenibut
docking on the MATs do, on the contrary, exhibit docking
scores, which vary according to the conformation used. This
can be ascribed to their larger structural flexibility and the
observed conformational changes upon optimization/exper-
imental crystal growth, particularly in the case of phenibut. In
line with our previous observations on the structural variations
for the different conformers of phenibut, we report these to
bear a greater impact on the yielded docking scores for the
DAT (S = −4.8739, −5.5775, and −4.1316 for quantum
mechanics, crystal structure, and molecular mechanics geo-
metries, respectively). In fact, the docking score for the
molecular mechanics-optimized geometry was computed to be
the lowest for all investigated ligand−MAT pairs. Underpinned
by the detailed structural analysis of the different yielded
conformations of the ligands, we associate this finding with the
observed endo-type arrangement of the protonated amine with
respect to the benzene core, hence resulting in fewer
intermolecular contacts with bordering amino acid residues.
While, to the best of our knowledge, there is a lack of
pharmacological studies on the interactions of phenibut with
the monoamine transporters, experimental observations made
for mexedrone interactions indicate higher potency values for
the NET.47 Along those lines, it is of note that our computed
docking scores employing the geometry of the crystal structure
(Table 1) are in agreement with these observations, whereas
scoring values for the conformations obtained following the
molecular docking protocol do not conform to the
experimental observations. Furthermore, the score for the
docking of the crystal structure conformation of mexedrone
onto the NET is the highest we report for all investigated
systems, largely attributed to close intermolecular interactions
with phenylalanine (43, 319, and 325) residues (Figures
S4.58−S4.60).
In light of these findings and to aid the development of
superior sensing platforms for these psychoactive substances
exploiting host−guest type chemistries, in the following, we
will explore in detail the determined intermolecular inter-
actions between the crystal structure geometries for each
ligand and nearest neighbor amino acid residues in all three
monoamine transporters.
Intermolecular Interactions, ΔECP. Intermolecular inter-
action energies were computed for the binding of the crystal
structure geometries of the psychoactive substances and
nearest neighboring amino acid residues in each monoamine
transporter, which were obtained from molecular docking
studies. First, we deemed of interest to compare the order of
the docking scores, which are calculated based on different
contributions and not solely the strength of the interaction,
with that of the overall computed intermolecular interaction in
each evaluated case, ΣΔECP. It is noteworthy that for the two
psychoactive substances for which pharmacological data is
available, namely, MDAI and mexedrone, our computed
Table 1. Computed Docking Scores for the Highest Ranked
Poses for the Different Ligand Geometries in All
Investigated Monoamine Transporters (MATs)
ligand conformation MAT docking score
MDAI quantum mechanics DAT −5.5362
NET −5.7010
SERT −5.0285
molecular mechanics DAT −5.5082
NET −5.6839
SERT −4.9237
crystal structure DAT −5.5249
NET −5.6946
SERT −5.0389
mexedrone quantum mechanics DAT −5.7706
NET −5.6254
SERT −5.1283
molecular mechanics DAT −4.8010
NET −4.8016
SERT −5.8647
crystal structure DAT −4.3128
NET −5.9837
SERT −4.9222
phenibut quantum mechanics DAT −4.8739
NET −5.5350
SERT −4.6779
molecular mechanics DAT −4.3116
NET −5.3696
SERT −5.1323
crystal structure DAT −5.5775
NET −5.3073
SERT −4.9307
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intermolecular interactions conform to the potency trends
observed experimentally for the three MATs. While docking
studies were also in agreement with experimental data in
relation to the activity of mexedrone, this was not the case for
the aminoindane MDAI for which docking results predicted
the highest potency on the NET (Table 1). In turn, ΣΔECP
results are consistent with experimental studies, which reveal
greater activity on the SERT, thus highlighting the importance
of the approach proposed herein. Predicted trends employing
computed intermolecular interactions for phenibut agree with
those obtained by molecular docking (vide supra).
Table 2 summarizes the computed intermolecular inter-
actions for MDAI with nearest neighbor amino acid residues in
all three monoamine transporters. Interestingly, despite the
different orientation of MDAI within the pocket of the DAT
and the NET, we identified that 10 out of the 12 nearest
neighbors that facilitate binding to the NET were also present
in the complex with the DAT, albeit exhibiting different
computed intermolecular interactions as a result of the distinct
relative three-dimensional orientation (ΔECP (Ala 117) =
−8.84 and −76.81 kJ mol−1 for DAT and NET, respectively).
In addition, none of these particular amino acid residues
contributes to the large computed binding of MDAI to the
SERT (ΣΔECP = −266.04 kJ mol−1).
In fact, we report the largest overall intermolecular
interactions for the binding of MDAI to the SERT, with
noteworthy stabilizing contributions from Ala 96 (ΔECP =
−44.76 kJ mol−1), Phe 335 (ΔECP = −54.61 kJ mol−1), and
especially Tyr 95 (ΔECP = −122.46 kJ mol−1) residues, all of
which exhibit interactions that engage their electronegative
carbonyl oxygen atoms and positively charged amine of the
ligand (Figure 4). The observed greater interaction with the
Tyr 95 residue can be further associated with (i) the closer
distance of the previously described interaction and (ii) the
additional T-shape-type interaction between the phenylalanine
phenol and the MDAI core. The latter finding exemplifies that
while selectivity toward a particular analyte in the design of
chemical sensors via judicious selection of peripheral
substitutions is appropriate, adequate selection of core motifs
also plays a critical role.
Similar to the observations made for the binding of MDAI,
we observe a large number of common amino acid residues
(11 out of 14 nearest neighbor NET residues) responsible for
the interaction of mexedrone within the central cavity of the
DAT and the NET. Despite the latter, there are significant
differences in the overall computed strength of the binding of
the ligand to those monoamine transporters. While we
compute mexedrone having the largest interaction energy to
the NET, we report the lowest value for the DAT, with the
overall interaction to the SERT somewhere in between
(ΣΔECP = −105.20, −182.53, and −158.53 kJ mol−1 for
binding to the DAT, the NET, and the SERT, respectively).
The approximately 2-fold increase in the ΣΔECP on
progression from the DAT to the NET can be particularly
associated with the contributions of two amino acid residues,
namely, Asp 46 and Phe 43. In evaluating this finding, we
observed that the large destabilizing interaction of mexedrone
with Asp 46 in the binding to the DAT, which can be
associated with a close contact between the electropositive
aspartic hydrogen atom of the acid group and the protonated
amine of the ligand, becomes almost negligible on binding to
the NET (ΔECP (Asp 46) = 28.76 and 2.48 kJ mol−1 for DAT
and NET, respectively). On the contrary, the stabilizing energy
computed for the mexedrone−Phe 43 pair in the DAT (ΔECP
= −24.44 kJ mol−1) was observed to increase significantly in
the case of the binding within the NET S1 site (ΔECP =
−59.10 kJ mol−1). We attribute the latter to the synergistic
contribution of the interaction between the electropositive
amine hydrogen atom and the electronegative carbonyl oxygen
at 2.625 Å as well as the stabilizing interaction of the
protonated mexedrone amine with the phenylalanine core
(Table 3).
Lastly, we focus on the individual amino acid contributions
on the binding of phenibut to the different monoamine
transporters. In contrast to the observations made for the other
two psychoactive substances where the lowest interactions
were computed for the binding to the DAT, we report the
largest overall interaction for phenibut when docked to this
monoamine transporter (ΣΔECP = −172.07, −117.37, and −
153.45 kJ mol−1 for binding to the DAT, the NET, and the
SERT, respectively). Upon judicious analysis of the binding of
the three ligands to the dopamine monoamine transporter, we
attribute the larger interaction energy of phenibut (ΣΔECP =
−158.77, −105.20, and − 172.07 kJ mol−1 for binding of
MDAI, mexedrone, and phenibut to the DAT, respectively) to
(i) a decrease of the destabilizing interaction with an aspartic
acid residue (Asp 46) and (ii) the increase of the binding
interaction to a tyrosine residue (Tyr 124) Figure 5.
In relation to the differences in the computed intermolecular
interactions between the psychoactive substances and the Asp
Table 2. Computed Counterpoise-Corrected Intermolecular
Interactions, ΔECP (kJ mol−1), for MDAI with Nearest
Neighboring Amino Acid Residues within the Binding Sites
of the DAT, NET, and SERT Monoamine Transporters
(Figures S4.1−S4.34)
DAT NET SERT
amino acid ΔECP amino acid ΔECP amino acid ΔECP
Ala 117 −8.84 Ala 117 −76.81 Ala 96 −44.76
Asp 46 21.53 Asn 125 −11.59 Asp 98 20.15
Asp 121 −13.89 Asp 46 6.32 Gly 338 5.60
Gly 425 3.57 Asp 121 −3.87 Gly 442 −3.25
Phe 43 −44.65 Gly 425 −6.86 Ile 172 −2.87
Phe 319 −52.99 Phe 43 −12.69 Phe 335 −54.61
Phe 325 −9.35 Phe 325 −22.21 Phe 341 −3.23
Ser 421 −5.16 Ser 421 −7.20 Ser 336 −39.33
Ser 422 −6.70 Ser 422 −23.12 Ser 438 −6.55
Tyr 124 −28.32 Ser 426 −13.92 Tyr 95 −122.46
Val 120 −13.97 Tyr 124 −16.39 Tyr 176 −14.73
Val 120 −24.91
Figure 4. Spacefill illustration of the interaction between MDAI and
Ala 96 (left), Phe 335 (center), and Tyr 95 (right) residues in the
binding to the SERT.
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46 residue (ΔECP = 21.53, 28.76, and 4.01 kJ mol−1 for binding
of MDAI, mexedrone, and phenibut to the Asp 46 residue,
respectively), these can be accounted for by means of the
greater interaction distance in the case of the binding to
phenibut as a result of a different three-dimensional arrange-
ment of the ligand within the central cavity of the transporter.
Likewise, the observed approximately 2-fold increase in the
stabilizing intermolecular interaction computed for the binding
the ligands to the tyrosine (Tyr 124) on progression from
MDAI and mexedrone to Phenibut (ΔECP = −28.32, −22.54,
and − 57.07 kJ mol−1 for binding of MDAI, mexedrone and
phenibut to the Tyr 124 residue, respectively) can also be
attributed to critical changes in the relative ligand−receptor
orientation within the S1 site of the DAT. In this case, we
observe that while binding of both MDAI and mexedrone is
facilitated by close T-shape interaction between aromatic
moieties of the ligands and the benzene core of the residue, the
increase in the computed ΔECP is associated with protonated
phenibut amine with the core of the amino acid (Table 4).
■ CONCLUSIONS
In conclusion, the binding of topical psychoactive substances
such as MDAI, mexedrone, and phenibut to the monoamine
transporters for dopamine, norepinephrine, and serotonin was
investigated to aid in the development of superior sensing
platforms for these target analytes that exploit host−guest type
chemistries. To do that and in light of the known structural
flexibility of most ligands and prior to docking studies, we
evaluated the conformational changes of optimized geometries
of the psychoactive substances by means of quantum as well as
molecular mechanics and compare them to experimentally
determined crystal structure geometries. Interestingly, in the
case of phenibut, it was observed that the molecular
mechanics-optimized geometry using SMILES string input
leads to a critically different conformer, where the endo-type
position of the protonated amine contrasts with the exo
orientation observed in the crystal structure and quantum
mechanics-optimized geometries. All conformers for each
ligand were then docked against target receptors using
molecular docking approaches. We observed that in the case
of MDAI, docking results for top ranked poses were influenced
by the conformation of the ligand and that experimentally
determined trends for the three transporters were not well
predicted by the computational methodologies. In turn,
computational trends obtained for the crystal structure
conformation of mexedrone conformed to experimental
observations, with a higher affinity for the interaction with
the NET. Subsequently, these results were further evaluated by
determining the intermolecular interactions between the
crystal structure geometries of the ligands and their nearest
neighbor amino acid residues in each monoamine transporter.
We found that the overall interaction energy computed for
MDAI was in agreement with experimental observations and
that the computed trends for mexedrone were further ratified.
In all cases, overall binding energies were rationally narrowed
down to contributions with key amino acids, which would be
critical in guiding the development of superior chemical
sensors. In particular, the greater interaction of MDAI with the
DAT when compared to that computed for its counterparts,
mexedrone and phenibut, was attributed to lower destabiliza-
tion upon interaction with the aspartic acid (46) residue and
more importantly to the strengthening of the interaction with
the tyrosine (124) residue within the S1 site of the transporter.
As a result, we believe the approach herein detailed to be of
interest for those engaged in the in silico evaluation of protein−
ligand interactions and to furthermore be invaluable in the
development of novel chemical sensors for biologically relevant
Table 3. Computed Counterpoise-Corrected Intermolecular
Interactions, ΔECP (kJ mol−1), for Mexedrone with Nearest
Neighboring Amino Acid Residues within the Binding Sites
of the DAT, NET and SERT Monoamine Transporters
(Figures S4.35−S4.74)
DAT NET SERT
amino acid ΔECP amino acid ΔECP amino acid ΔECP
Ala 44 −16.46 Ala 44 −12.72 Asp 98 6.1447
Ala 48 3.01 Ala 117 −9.05 Glu 493 −68.37
Asp 46 28.76 Asp 46 2.48 Ile 172 −4.22
Asp 121 −5.72 Asp 121 −1.28 Phe 335 −22.84
Gly 322 −1.46 Gly 322 −2.82 Ser 438 −6.08
Gly 425 6.84 Gly 452 2.22 Thr 497 −15.74
Leu 321 −8.35 Leu 321 −9.04 Tyr 95 −20.49
Phe 43 −24.44 Phe 43 −59.10 Tyr 175 −16.03
Phe 319 −50.63 Phe 319 −32.44 Tyr 176 −13.08
Phe 325 2.22 Phe 325 −18.64 Val 501 2.18
Ser 320 −5.33 Ser 320 −21.18
Ser 421 −6.11 Ser 421 0.45
Ser 422 2.71 Tyr 124 −12.77
Tyr 124 −22.54 Val 120 −8.64
Val 120 −7.70
Figure 5. Spacefill representation of the interaction MDAI (left),
mexedrone (center), and phenibut (right) with the Tyr 124 residue
within the S1 site of the DAT.
Table 4. Computed Counterpoise-Corrected Intermolecular
Interactions, ΔECP (kJ mol−1), for Phenibut with Nearest
Neighboring Amino Acid Residues within the Binding Sites
of the DAT, NET, and SERT Monoamine Transporters
(Figures S4.75−S4.112)
DAT NET SERT
amino acid ΔECP amino acid ΔECP amino acid ΔECP
Ala 44 −0.65 Ala 44 −9.04 Ala 96 −27.69
Ala 117 −15.48 Ala 48 3.74 Asp 98 8.65
Asp 46 4.01 Asp 46 −5.14 Gly 338 −0.38
Gly 332 −3.05 Phe 43 −29.19 Gly 442 −0.15
Gly 425 4.53 Phe 319 −9.69 Ile 172 −4.62
Leu 321 −9.59 Phe 325 −18.64 Leu 337 −1.23
Phe 43 −33.13 Ser 320 −21.19 Phe 335 −50.92
Phe 319 −15.16 Ser 421 −6.99 Phe 341 −7.74
Phe 325 −7.22 Ser 422 0.18 Ser 336 −13.41
Ser 320 −8.17 Tyr 124 −12.77 Ser 438 −3.18
Ser 421 −4.12 Val 120 −8.64 Tyr 95 −33.68
Ser 422 −4.13 Tyr 176 −21.34
Tyr 124 −57.07 Val 97 2.24
Val 120 −22.84
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analytes via judicious selection of peripheral substitutions
performed on core motifs with the desired optoelectronic
properties.
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